Xenon Pharmaceuticals Inc. (XENE) intrinsic value & 10-year financials
Xenon Pharmaceuticals Inc. (XENE) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 17.2% a year to $7.5M, with an average return on invested capital of -56.9%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $33.49
- Market cap
- $2.7B
- Revenue (FY2025)
- $7.5M
- Revenue growth (10-yr CAGR)
- 17.2%
- ROIC (10-yr avg)
- -56.9%
- Free cash flow (FY2025)
- -$279.9M
XENE 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $7.5M | -$345.9M | -$4.36 | -$279.9M | -4974.3% | -74.0% |
| FY2024 | $0 | -$234.3M | -$3.01 | -$184.5M | — | -39.0% |
| FY2023 | $0 | -$182.4M | -$2.73 | -$150.9M | — | -29.2% |
| FY2022 | $9.4M | -$125.4M | -$2.06 | -$101.3M | -1368.9% | -24.5% |
| FY2021 | $18.4M | -$78.9M | -$1.77 | -$71.6M | -428.4% | -30.9% |
| FY2020 | $32.2M | -$28.8M | -$0.81 | -$50.8M | -97.3% | -29.1% |
| FY2019 | $6.8M | -$41.6M | — | -$5.9M | -627.0% | -63.8% |
| FY2018 | — | -$34.5M | -$1.63 | -$35.2M | — | -104.4% |
| FY2017 | $311.0K | -$30.7M | -$1.72 | -$29.0M | -10474.3% | -138.0% |
| FY2016 | $1.8M | -$23.0M | -$1.48 | -$19.8M | -1376.4% | -36.0% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Xenon Pharmaceuticals Inc. is a consistent compounder, expanding top-line revenue at 17.2% annually over the past decade.
Xenon Pharmaceuticals Inc. has historically struggled to out-earn its cost of capital, averaging just -56.9% ROIC.
Xenon Pharmaceuticals Inc. has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Xenon Pharmaceuticals Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-144.82 per share.